September 29, 2025, Jeddah, Saudi Arabia – The inauguration ceremony for the Fosun Pharma Middle East Office and Fosunhenlius Middle East United Company was grandly held in Jeddah, Saudi Arabia. This move marks a significant step in Fosun Pharma's localized operations in the Middle East, representing a strategic initiative by the company to continuously expand its global presence through innovation.

Distinguished guests present at the ceremony included Dr. Mazen Fakeeh, SVax Chairman, and Prof. Mazen Hassanain, SVax Managing Director and CEO, Wang Qimin, Consul General of China in Saudi Arabia; Wang Qunbin, Co-CEO of Fosun International; Chen Yuqing, Chairman of Fosun Pharma; as well as senior management from Saudi Arabia's MISA investment authority and local partners. They jointly participated in the ribbon-cutting ceremony for the Fosun Pharma Middle East Office, witnessing this important moment.

Currently, Fosun Pharma has established mature commercial networks in overseas markets such as the United States, Europe, Africa, India, and Southeast Asia, boasting an overseas commercial team of approximately 1,000 people. In the Middle East, Fosun Pharma is steadily advancing deep cooperation with local partners and the registration process for innovative drugs: In April 2025, Fosun Pharma entered a strategic cooperation with Saudi Arabia's Fakeeh Care Group to jointly promote the introduction of innovative products and therapies; In August 2025, Fosun Pharma’s self-developed innovative drug Luvometinib Tablets received Breakthrough Therapy Designation from the Saudi Food and Drug Authority, which will accelerate its clinical registration and commercialization process in Saudi Arabia.

For almost a decade, SVax has been at the forefront of Saudi Arabia’s efforts to localize vaccine and biologics manufacturing in line with Vision 2030 and the Saudi National Biotechnology Strategy. With its strong foundation in regulatory affairs, market access, and commercialization, SVax played a central role in the formation of the Fosunhenlius Middle East United Company, ensuring that the joint venture is firmly rooted in the Kingdom’s healthcare priorities. By leveraging its local expertise, networks, and talent pool, SVax is not only enabling the introduction of world-class biologics into Saudi Arabia but also helping to establish a resilient biomanufacturing ecosystem that will serve patients across the broader MENAT region

Fosunhenlius Middle East United Company is a strategic joint venture between SVax, a pioneering Saudi biopharmaceutical company, and Henlius, a global innovative biopharmaceutical enterprise under Fosun Pharma. Headquartered in Saudi Arabia, the company integrates world-class biologics R&D and manufacturing capabilities with deep local expertise in registration, commercialization, and healthcare access. Its mission is to bring affordable, high-quality biologics in oncology, autoimmune, and other critical therapeutic areas to patients across Saudi Arabia and the broader MENAT region. In alignment with Saudi Vision 2030 and the National Biotechnology Strategy, the company is committed to building a resilient local biomanufacturing ecosystem and driving innovation that transforms healthcare delivery in the region.

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with SinopharmGroup Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy - Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powereddrug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence, and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.